Bengaluru, Karnataka, India, November 18, 2026
Biocon Limited has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo® (pertuzumab), its biosimilar for HER2-positive breast cancer, across multiple stages of the disease in the European Union (EU). The approval represents a significant regulatory milestone because Pebrilzo is the first biosimilar to receive European Commission marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. The decision follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026. The authorization strengthens Biocon’s international oncology portfolio and expands its presence in the global biosimilars market. It also supports the company’s strategy of developing high-quality, affordable biologic medicines for patients and healthcare systems.
First Biosimilar Approved Under EMA’s Tailored Clinical Approach
The European Commission’s decision marks an important development in the European biosimilar regulatory pathway. Under the EMA’s tailored clinical approach, the evidence required to demonstrate biosimilarity can be adapted according to the characteristics of the reference medicine and the available analytical, functional and clinical data. This approach places emphasis on comprehensive scientific characterisation and comparative evidence to establish that a proposed biosimilar is highly similar to its reference product, without clinically meaningful differences in quality, safety or efficacy. Biocon’s pertuzumab biosimilar is the first to receive EC marketing authorization through this approach, highlighting the growing role of advanced analytical methods and evidence-based regulatory assessment in biosimilar development. The authorization follows the positive CHMP opinion issued in September 2026 and represents the completion of the European regulatory review process for the product. According to Biocon, the approval also follows the recent U.S. Food and Drug Administration (FDA) approval of its pertuzumab biosimilar, further strengthening its regulatory position in major international markets.
Pebrilzo Targets HER2-Positive Breast Cancer
Pebrilzo is a 420 mg concentrate for solution for infusion containing pertuzumab as its active substance. Pertuzumab is a monoclonal antibody that binds specifically to the human epidermal growth factor receptor 2 (HER2), a protein that can be overexpressed in certain breast cancers. By binding to HER2, pertuzumab interferes with receptor signalling involved in tumour-cell growth and proliferation. The EU authorization covers several treatment settings in adult patients with HER2-positive breast cancer. In combination with trastuzumab and chemotherapy, Pebrilzo is indicated for neoadjuvant treatment of patients with locally advanced, inflammatory or early-stage breast cancer who are at high risk of recurrence. It is also authorized for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. Additionally, in combination with trastuzumab and docetaxel, it is indicated for adults with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for their metastatic disease. These indications position the biosimilar for use across different stages of HER2-positive breast cancer management.
Analytical Evidence Strengthens Biocon’s Biosimilar Portfolio
Biocon reported that the development and regulatory assessment of its pertuzumab biosimilar included extensive structural and functional analytical characterisation, supported by comparative clinical pharmacokinetic data. These assessments demonstrated a high degree of similarity between Pebrilzo and the reference product, with no clinically meaningful differences in quality, safety or efficacy. Such evidence is central to biosimilar development because it establishes that the proposed product is sufficiently similar to the original biologic to support the same therapeutic use. According to Shreehas Tambe, CEO and Managing Director of Biocon, the European approval makes pertuzumab the company’s fifth oncology biosimilar approved in both Europe and the United States. The milestone further expands Biocon’s oncology portfolio, which includes treatments for solid tumours such as breast cancer, as well as supportive-care and bone-health therapies.
Breast cancer remains the most commonly diagnosed cancer among women in Europe, and approximately 15–20% of invasive breast cancers are HER2-positive. Expanding access to HER2-targeted biologic medicines is therefore an important consideration for patients and healthcare systems. Biosimilars can contribute to treatment affordability and competition while maintaining the established clinical standards of the reference biologic. With European marketing authorization secured, Pebrilzo represents a further step in Biocon’s global oncology strategy. The company stated that the approval reinforces its commitment to expanding access to biologic therapies across international markets. The EU authorization is a regulatory milestone for biosimilar access and does not, by itself, confirm the timing of commercial launch in individual countries.
Source: Biocon press release



